Evelo Biosciences, Inc. EVLO

EVLO Company Overview

Evelo Biosciences, Inc. (NASDAQ formerly: EVLO) is a biotechnology company focused on developing therapies that act through the small intestinal axis to influence systemic immune and inflammatory responses. The company historically operated within the immunology and inflammation segments of the biopharmaceutical industry, with research centered on orally delivered biologic products designed to modulate immune pathways without broad systemic exposure. Evelo’s development programs targeted inflammatory diseases, oncology-related immune modulation, and metabolic conditions through interactions between the gut and the immune system.

The company’s primary value proposition was based on its proprietary “SINTAX” platform, which sought to leverage the small intestine as a therapeutic target for systemic disease modulation. Evelo was founded in 2014 and advanced several clinical-stage programs over the following years, including candidates for psoriasis and other inflammatory disorders. Public filings and market disclosures indicate that the company underwent significant restructuring following clinical setbacks and financing challenges. Data regarding long-term operational continuity and strategic outcomes after restructuring is inconclusive based on available public sources.